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Recent  publications  from this laboratory (1,  2)  have shown that  it  is possible  to 
cause the regression of established immunogenic murine tumors by the passive transfer 
of tumor-sensitized  T  cells  from  immunized  donors,  provided  the  tumor-bearing 
recipients have been made T  cell-deficient by thymectomy and irradiation. The need 
for  T  cell-deficient  tumor-bearing  recipients  to  demonstrate  successful  adoptive 
immunotherapy suggested the existence in normal tumor bearers ofa T cell-dependent 
mechanism that prevents intravenously infused sensitized T cells from expressing their 
antitumor  function.  Evidence  that  this  obstacle  to  adoptive  immunotherapy  is  a 
tumor-induced, T  cell-mediated mechanism of immunosuppression was supplied by 
the demonstration (3, 4) that the passive transfer of splenic T cells from normal tumor 
bearers prevents passively transferred tumor-sensitized T  cells from causing tumors to 
regress  in  T  cell-deficient  recipients.  It  was  hypothesized, on  the  basis  of this  and 
other evidence (5) that the growth of an immunogenic tumor results in the generation 
of a  state of T  cell-mediated immunosuppression that  functions to "down-regulate" 
a preceding concomitant immune response. Hence, the explanation for the paradox- 
ical growth of immunogenic tumors in their immunocompetent hosts, and the reason 
why these tumors develop refractoriness to active and adoptive immunotherapy. 
In designing experiments  to investigate the mode of action of suppressor T  cells, 
two aspects of this model of adoptive immunotherapy need to be considered. The first 
is that the sensitized T  cells routinely used to passively transfer anti-tumor immunity 
are obtained from donor mice that are immunized by causing their tumor to regress 
2-3 wk earlier by intralesional  therapy with  Corynebacterium parvum.  The sensitized T 
cells  are  harvested,  therefore,  after the cytolytic T  cell  response to the  immunizing 
tumor has decayed (6) and when the donors possess a state of immunological memory. 
Thus, the sensitized T cells infused intravenously have no detectable cytolytic activity 
of their own. The second important aspect of the model is that the passive transfer of 
tumor-sensitized T  cells  does not result in an immediate onset of tumor regression in 
T  cell-deficient recipients. Instead, there is invariably a 6-8-d delay before regression 
commences. It can be postulated, therefore, that the intravenously infused sensitized 
T  cells  do not possess  the capacity themselves to immediately destroy the tumor, but 
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impart  to  the  tumor-bearing recipient the ability to  generate a  new population of 
effector T  cells in response to tumor antigens over a  6-8-d period. 
This paper will show that the passive transfer of noncytolytic, tumor-sensitized T 
cells does  not cause the  regression of tumors growing in T  cell-deficient recipients 
until an adequate number ofcytolytic T  cells are generated in the recipients' draining 
lymph nodes. It will show, in addition, that a cytolytic T  cell response of much lower 
magnitude is generated in normal tumor-bearing recipients of immune T  cells, and 
that  a  similar low magnitude response is generated in T  cell-deficient recipients of 
immune T  cells that  are  also  infused with  suppressor  T  cells  from  tumor-bearing 
donors. The results indicate that suppressor T  cells inhibit adoptive immunotherapy 
by inhibiting the production of cytolytic T  cells in the tumor-bearing recipient. 
Materials and Methods 
Mice.  B6D2F1  (C57BL/6  ×  DBA/2)  mice, 9-14 wk old, were supplied by the Trudeau 
Institute Animal Breeding Facility. The mice were free of known viral pathogens according to 
the results of routine serological screening performed by the Animal Diagnostic Testing Service 
of Microbiological Associates,  Walkersville, MD. 
Tumors.  The P815 mastocytoma, syngeneic in DBA/2 mice, was originally obtained from 
Dr.  Virginia Evans, Tissue Culture Section, National Cancer Institute. The P815  tumor is 
passaged weekly as an intraperitoneal ascites,  and a new passage is initiated every 3 mo from 
tumor stocks that are cryopreserved over liquid nitrogen in RPMI 1640 (Gibco Laboratories, 
Grand Island, NY)  containing 20% fetal bovine serum (FBS) 1 (Sterile Systems, Logan, UT) 
and  10%  dimethylsulfoxide (Mallinckrodt, Inc.,  St.  Louis,  MD).  The  L5178Y  and  P388 
lymphomas syngeneic in  DBA/2  mice  were  obtained from  Dr.  E.  F.  Wheelock,  Thomas 
Jefferson University, Philadelphia, PA and the EL-4 thymoma, syngeneic in C57BL/6 mice, 
was  obtained  from  Dr.  Virginia  Evans.  These  tumors  were  passaged  as  an  ascites  and 
cryopreserved in a similar manner to the P815 tumor. All of the tumors were free of known 
viral pathogens according to the results of serological screening performed by Microbiological 
Associates. 
For tumor implantation, ascites  tumor cells  were  harvested in phosphate-buffered saline 
(PBS) containing 10 U of heparin/ml, washed, and resuspended to an appropriate number in 
PBS. Intrafootpad tumors were initiated by implanting l0  s tumor cells in a volume of 0.05 ml 
PBS  in the right hind footpad. Tumor growth was monitored by measuring changes in the 
dorsoventral thickness of the footpad with dial calipers. 
Adoptive  Immunization.  Mice  used  as  immune donors were  immunized against the  P815 
tumor by injecting them intradermally with 2 ×  l0  s P815 tumor cells admixed with 100/zg of 
Cotynebacterium parvum  (Burroughs Wellcome, Greenville, NC). It is known that this immuniza- 
tion protocol results in a  9-d period of tumor growth followed  by complete and permanent 
tumor regression by 3 wk in 80-90% of mice. Donor mice were used 3 wk after immunization. 
For cell transfer, spleens of immunized mice or of tumor-bearing mice were diced into small 
pieces  and passed through a  60-mesh stainless steel  screen using cold PBS containing 0.5% 
syngeneic mouse serum. The resulting cell suspension was washed and filtered through sterile 
surgical gauze to remove debris and cell  clumps. The cells  were  infused intravenously in a 
volume of 1 ml. 
Recipient mice were made T  cell-deficient (TXB) by thymectomy at 5 wk of age, followed 
7 d later by exposure to 900 rads of whole-body gamma irradiation from a  IaTCs source. They 
received an intravenous infusion of 10  ~ syngeneic bone marrow cells immediately after irradia- 
tion and were used in experiments after a further 4 wk. 
51Cr-release Assay.  The details of the assay system have been described previously (6). P815 
tumor cells to be used as target cells in cytotoxicity assays were grown in RPMI 1640 containing 
15%  heat-inactivated horse serum  (HS),  100 /~g/ml  streptomycin, and  100 U/ml penicillin. 
1 Abbreviations used in  this paper: C', complement; FBS, fetal bovine serum; HS, horse serum; MOPS, 
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Unless indicated,  these and other tissue culture reagents were purchased  from Gibco Labora- 
tories. Tumor cells were harvested during log phase growth, and  106 cells were labeled in 0.4 ml 
of the medium containing 100/~Ci of Na251CrO4  (CJS. 11; Amersham Corp., Arlington Heights, 
IL).  The  L5178Y  and  P388  lymphomas,  and  the  EL-4  thymoma  were  grown  in  vitro and 
labeled with 5iCr in the same manner as the P815 tumor. 
Effector cells from the draining lymph nodes of adoptively immunized and control tumor- 
bearing  recipients were harvested  by  pressing  finely diced  pieces of lymph  nodes  through  a 
stainless steel screen using Hanks' balanced salt solution containing 1% FBS, antibiotics, and 10 
mM  morpholinopropane  sulfonic acid  (MOPS)  (Sigma Chemical Co.,  St.  Louis, MO).  The 
lymph  node cells were then  centrifuged and  resuspended  to an appropriate  concentration  in 
assay  medium  that  consisted  of RPMI  1640  supplemented  with  10%  HS,  antibiotics,  and 
MOPS. The assay was performed in triplicate with plates containing 96 round-bottomed wells 
(Flow Laboratories, Inc., McLean, VA).  Except where indicated, each well contained 5 ×  105 
effector cells and  104 51Cr-labeled target cells in a  total volume of 200/~1 of medium. After a 6- 
h  incubation  at  37°C in an atmosphere of 7% CO2 in air, 50/zl of supernatant  was removed 
from each  well and  counted  in  a  Rack Gamma  II gamma counter  (LKB  Instruments,  Inc., 
Gaithersburg, MD). Total 51Cr-release was the amount of 51Cr released from the target cells by 
treatment  with 0.5% Triton-X. Total release was >97%, and spontaneous release ranged from 
8  to  12%  of  the  total  release.  The  percent  specific  SICr-release  was  calculated  as  follows: 
[(experimental cpm -  spontaneous cpm)/(total cpm -  spontaneous cpm)]  X  100. 
Antibody  Treatment.  Hybridomas  secreting  monoclonal  anti-Thy-l.2  (30-H12),  anti-Lyt-1 
(53-7.313),  and  anti-Lyt-2  (53-6.72)  antibody  (7)  were  obtained  from  the Salk Institute,  La 
Jolla, CA. The cells were grown to 5  X  10  s cells/ml in RPMI  1640  supplemented  with  10% 
FBS and antibiotics. The cultures were subjected to centrifugation and the supernatants  were 
collected and stored at -20°C until required. Rabbit sera used as a source of complement (C') 
were obtained  from rabbits  bred  at  the Trudeau  Institute.  The rabbits  were selected on the 
basis of minimum toxicity of their sera  for mouse leukocytes.  Mouse anti-rat  IgG serum was 
raised  by injecting mice with  100/tg of rat  IgG  (Cappell  Laboratories,  Cochranville, PA)  in 
Freund's complete adjuvant. The mice were given two additional injections of rat IgG in 0.5 ml 
of Freund's incomplete adjuvant,  intraperitoneally,  and two injections of the antigen intrave- 
nously  in  PBS.  Serum  was  collected 6  d  later,  heat  inactivated,  and  stored  at  -20°C  until 
required. The media used for antibody treatments consisted of RPMI  1640 supplemented with 
1% FBS, antibiotics, and MOPS. 
For T  cell depletion, lymph node cells (4 X  107/ml) were incubated at 4°C for 40 min in a 
1:5  dilution  of the  anti-Thy-l.2  culture  supernatant.  An  equal  volume of a  1:5  dilution  of 
rabbit  C' was then  added,  and  the cells were incubated  at  37°C for a  further  60 min. They 
were then washed,  counted,  and  resuspended  to the appropriate  concentration  for use in the 
51Cr-release assay.  Preliminary  studies  showed  that  treatment  with  anti-Thy-l.2  +  C' killed 
>96% of thymocytes and decreased the ability of normal spleen cells to respond to concanavalin 
A or phytohemagglutinin by >99%.  For depletion of Ly T  cell subsets,  lymph node cells (2 X 
10V/ml)  were incubated  at 4°C for 40 min in a  1:5  dilution of the anti-Ly-1  or the anti-Ly-2 
culture supernatants.  The preparation  was then centrifuged and the cells were resuspended at 
4 ×  107/ml in a  1:50 dilution of mouse anti-rat IgG serum and incubated at 4°C for a  further 
40 min. The cells were then treated with rabbit serum as above. 
Winn Assay.  Lymph node or spleen cells to be tested for their ability to inhibit tumor growth 
in vivo (8)  were admixed at 4°C either at a  10:1  or a  3:1 ratio with 5 ×  106 P815  tumor cells. 
Immediately  thereafter,  the  admixtures  were  injected  in  a  volume of 0.05  ml  into  a  hind 
footpad of mice that  had  been irradiated  (700 rad)  earlier the same day.  Tumor growth was 
measured with dial calipers. 
T  Cell Enrichment.  Lymphoid  cell suspensions  were enriched  for T  cells using anti-mouse 
IgG-coated plates by a  previously described procedure  (6). 
Results 
Onset  of  Tumor  Regression  is  Preceded  by  Cytolytic  T  Cell  Production  in  Recipients.  A 
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P815 tumors to regress in T  cell-deficient mice, but not in normal mice. It also showed 
that tumor regression does not commence in TXB recipients until after a 6-8-d delay. 
It was necessary to determine,  therefore, whether the delay before tumor regression 
commences in T  cell-deficient recipients represents the time needed for the recipients 
to generate an adequate number of cytolytic T  cells of their own, and whether failure 
of tumors to regress in normal recipients is associated with an inadequate production 
of cytolytic T  cells. 
It can be seen in Fig.  1 that, in agreement with previous studies (1, 2), intravenous 
infusion of 2 ×  108 spleen cells from tumor-immune donors caused tumors to regress 
in T cell-deficient, but not in normal recipients. It can be seen, in addition, that tumor 
regression in T  cell-deficient recipients did not commence until cytolytic T  cells were 
generated in the lymph node draining the tumor. The cytolytic response did not begin 
until 3 d after the passive transfer, and peaked 4 d later at the time of onset of tumor 
regression. The cytolytic response then underwent rapid decline. In contrast, and as 
would be expected, tumor-bearing T  cell-deficient mice made no detectable cytolytic 
T cell response. Fig. 1 also shows that the failure of tumors to regress in T cell-deficient 
recipients  infused  with  normal  spleen  cells  was  associated  with  a  cytolytic T  cell 
response of much lower magnitude. Finally, it can be seen that passively transferred 
immune  spleen  cells  gave  no  greater  cytolytic response  in  normal  tumor-bearing 
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FEC.  1.  Evidence that the onset of tumor regression in T  cell-deficient  recipients of 2 ×  l0  s spleen 
cells from immune donors is preceded by the production in the recipients' draining lymph node of 
T  cells cytolytic for P8 1  5 tumor cells in vitro. Failure of TXB recipients of normal spleen cells and 
of normal recipients of immune cells to destroy their tumors was associated with a cytolytic response 
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recipients  than  that  generated  by  normal  mice  in  response  to  progressive  tumor 
growth.  It is apparent,  therefore,  that  an  established tumor  does not  commence  to 
regress in an adoptively immunized recipient until a large enough number of cytolytic 
effector T  cells are  generated:  a  number  that  can  be  generated  in T  cell-deficient 
recipients, but not in normal recipients of sensitized T  cells. 
The apparent  need for the generation of an adequate number of cytolytic T  cells 
to  cause  tumor  regression  in  TXB  recipients  is  illustrated  by  the  results  of  an 
additional experiment that tested the effect of infusing graded numbers of sensitized 
T  cells on cytolytic T  cell production and tumor growth. Fig. 2 shows that increasing 
the  number  of sensitized T  cells infused  resulted  in  corresponding  increases in  the 
magnitude  of the  recipients' cytolytic T  cell response  and  the  extent  to  which  the 
tumors  regressed.  It  is apparent  from  Fig.  2  that  passive transfer  of >108  immune 
spleen cells into tumor-bearing TXB mice is necessary to generate a cytolytic response 
of sufficient magnitude to cause complete tumor regression in a  majority of recipient 
mice. 
Cytolytic Cells are Tumor-specific Ly-2  + T  Cells.  Some of the properties of cytolytic T 
cells generated at peak response in T  cell-deficient tumor-bearing recipients of tumor- 
sensitized T  cells are shown  in Fig. 3.  It can  be seen that  the cytolytic cells were T 
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Fro.  3.  Properties of cytolytic cells harvested at peak response from the draining lymph node of 
tumor-bearing TXB  recipients of immune T  cells. Cytolytie activity was  totally eliminated by 
treating the lymph node cells with anti-Thy-l.2 antibody and C', or with anti-Ly-2-antibody and 
C'.  (A) Cytolytic function was partially eliminated with anti-Ly-1 antibody and C' treatment. 03) 
T  cell cytolytic activity was directed at P815 targets, but not against two other DBA/2 tumors, the 
P388 and L5178Y lymphomas, or a C57BL/6 tumor, the EL-4 lymphoma. 
cells  as evidenced by the  finding  that  their  ability to lyse 5ZCr-labeled targets was 
completely ablated  by incubation  with  monoclonal  anti-Thy-l.2  antibody and  C'. 
Their  cytolytic activity also was  totally eliminated  by treatment  with  monoclonal 
anti-Ly-2 antibody and C' and was partially eliminated with monoclonal anti-Ly-1 
and C'. Therefore, all of the cytolytic T  cells display the Ly-2 antigen and a proportion 
of them also display enough Ly-1 antigen  to make them susceptible to complement 
mediated lysis by the particular anti-Ly-1 monoclonal antibody used. 
The specificity of the cytolytic T  cells for the P815 mastocytoma is shown in Fig. 3 
where it can be seen that they were not capable of lysing two other DBA/2 tumors, 
the L5178Y and P388 lymphomas, or a  C57BL/6 tumor, the EL-4 thymoma. These 
three tumors are known to release S~Cr after lysis by appropriate effector T  cells. 
To verify that the ability of cytolytic T  cells to cause 5ZCr release from P815 tumor 
targets  in  vitro was  a  measure of their capacity to  prevent  tumor growth  in  vivo, 
cytolytic T  cells were harvested  at peak response from adoptively immunized TXB 
recipients and tested in a Winn assay (8) in secondary recipients. It can be seen in Fig. 
4 that cytolytic T  cells harvested from the popliteal lymph nodes of tumor-bearing T 
cell-deficient recipients that had been infused 8 d earlier with tumor-immune spleen 
cells completely prevented the growth of P815 tumor cells in the footpads of secondary 
recipients at a  10:1  or a  3:1 effector cell to tumor cell ratio. As was found in the 5ZCr- 
release assay, the  ability of cytolytic T  cells  to  prevent  P815  tumor growth  in  the 
Winn  assay was  abolished  by treatment  with  anti-Ly-2 antibody and  C', and  was 
partially eliminated by treatment with anti-Ly-1 antibody and C', In contrast to the 
results obtained with cytolytic T  cells generated as part of a  secondary response in 
tumor-bearing recipients, the spleen cells from tumor-immune donors used to adop- 
tively immunize these recipients possessed no capacity to prevent the growth of tumor 
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FiG.  4.  Demonstration that lymph node cells harvested at peak cytolytic response and at t'he time 
of onset of tumor regression in adoptively immunized tumor-bearing TXB recipients were capable 
of inhibiting tumor growth in vivo. When 5 ×  10  e P815 cells were admixed with (A)  5 ×  106 or (B) 
1.67  X  106 lymph node ceils and the admixture injected into the left hind footpad of irradiated 
recipients, the tumor cells failed to grow. The ability of lymph node cells to inhibit tumor growth 
was abolished by treating them with anti-Ly-2 antibody and C' treatment (A, B), and was partially 
abolished by treatment with anti-Ly- 1 antibody and complement treatment (B). Spleen cells of the 
primary donor used to adoptively immunize TXB recipients did not inhibit tumor growth, even 
though they were enriched for T  cells by incubation in anti-mouse I8(3 coated plates (A). 
cells according to the Winn assay, even though the spleen cells were enriched for T 
cells by panning on anti-mouse IgG-coated plates (Fig. 4). 
Inhibition of Adoptive Cytolytic T  Cell Production by Suppressor Cells from  Tumor-bearing 
Donors.  The  foregoing  results  serve  to  confirm  previous  findings  (1,  2)  that  it  is 
possible to cause tumors to regress by the passive transfer of tumor-sensitized T  cells, 
but only if the tumors are growing in T  cell-deficient recipients.  More importantly, 
they serve to  indicate  the  reason  why passively transferred  sensitized  T  cells cause 
tumors to regress in T  cell-deficient, but not in normal recipients. They show that it 
is only in the former that intravenously infused immune T  cells are able to give rise 
to the production of an adequate number of cytolytic effector T  cells. On the basis of 
results of previous studies  (3, 4), which showed normal tumor bearers possess T  cells 
that  can  suppress  the  expression  of adoptive  immunity  in  TXB  recipients,  it  was 
postulated  that  failure  of  passively  transferred  immune  T  ceils  to  cause  tumor 
regression and give rise to the generation of an adequate number of cytolytic T  cells 
in  normal  tumor-bearing  recipients  is  due  to  the  presence  in  these  recipients  of 
suppressor T  cells.  This was investigated by determining whether spleen cells  from 
donors with  established  P815  tumors are capable, on passive transfer,  of inhibiting 
the  generation  of cytolytic  T  cells  in  T  cell-deficient  tumor-bearing  recipients  of 
immune spleen cells. 
It can be seen in Fig.  5, in agreement with the foregoing results, that intravenous 
infusion of T  cell-deficient tumor-bearers with immune spleen cells resulted, after a 
delay,  in  the  generation  of cytolytic  T  cells  in  the  draining  node  and  progressive 
tumor regression. It can be seen in addition, however, that if the recipients of immune 
spleen cells were infused  1 h  later with spleen cells from donors with  15-d progressive 
tumors, a cytolytic T  cell response of much lower magnitude was generated, and the 
tumors underwent only partial regression and then regrew. In contrast, an infusion of 
normal spleen  cells had no such  inhibitory  effect on cytolytic T  cell production  or 
tumor regression. 40-- 
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FIo.  5.  Evidence that suppressor T  cells from mice with progressive P815 tumors inhibit adoptive 
immunotherapy of an established tumor in TXB recipients by suppressing an adoptive cytolytic 
response in the recipients. Tumor regression failed to occur in TXB recipients of immune T  cells if 
the recipients were also infused with suppressor T  cells (A)  and this was associated with a  greatly 
reduced production of cytolytic T  cells (B) in the draining lymph node. Infusion of normal T  cells, 
instead of suppressor T  cells,  had  no  inhibitory  effect  on  tumor  regression or  cytolytic  T  cell 
production. 
Discussion 
The results of this study show that the expression of passively transferred, T  cell- 
mediated immunity against established P815 tumors growing in TXB recipient mice 
does not begin until a secondary cytolytic T cell response is generated in the recipients. 
It  is apparent,  therefore, that  the 6-8 d  delay that  invariably occurs before tumor 
regression commences represents the time needed for the intravenously infused, tumor- 
sensitized T  cells to give rise to the production of effector or mediator T  ceils.  This is 
not surprising, in view of the fact that the tumor-sensitized T  cells routinely used for 
adoptive immunity have no cytolytic activity of their own. They are harvested from 
immunized donors well after the production of cytolytic T  cells to immunizing tumor 
antigens has decayed, and when the donors possess a state of immunological memory 
(6). It should be pointed out, moreover, that the donors themselves need to generate 
a secondary cytolytic T  cell response before they can reject a challenge implant of the 
immunizing  tumor  (C.  D.  Mills  and  R.  J.  North,  manuscript  in  preparation). 
Therefore, the sensitized T  cells infused intravenously were memory or helper T  cells. 
There are  three main  findings  that justify postulating  that  cytolytic T  cells are 
required for tumor regression. The first is that tumor regression was preceded, in every 
case, by peak production of cytolytic T  cells in the draining node. Second, the larger 1456  CYTOLYTIC T  CELLS IN ADOPTIVE TUMOR IMMUNOTHERAPY 
the number of cytolytic T  cells generated in recipients at peak response, the greater 
was the extent of tumor regression in the recipients. Third, tumor regression failed to 
occur  unless  cytolytic  T  cell  production  exceeded  a  certain  minimal  level.  These 
findings,  together with  the  knowledge that  the T  cells  generated  in  the  recipient's 
lymph nodes,  in  contrast  to donor T  cells,  lysed P815  tumor targets specifically in 
vitro and were capable of neutralizing the growth of a P815 implant in vivo, represent 
strong  circumstantial  evidence  that  cytolytic  T  cells  are  involved  in  the  rejection 
process. The additional finding that the cytolytic T  cells are of the Ly-2  + phenotype, 
but that some of them also display Ly- 1 antigen, is consistent with evidence published 
by others about cytolytic T  cells in general  (9-12)  and with the knowledge (13)  that 
most T  cells express the Ly-1 antigen to some degree. 
Even so, evidence has been published by others  (14)  that has been interpreted as 
showing that cellular mechanisms other than, or in addition to, cytolytic T  cells may 
be responsible for allograft or tumor rejection. It has been demonstrated, for example, 
that the rejection of skin or tumor allografts in TXB recipient mice can be achieved 
by the passive transfer of Ly-1  + helper T  cells, to the exclusion of Ly-2  + T  cells that 
were eliminated  by treatment  with anti-Ly-2 antibody and C'. On  the basis of the 
view that Ly-l+2  -  T  cells cannot change into Ly-2  ÷ T  cells (10,  15), coupled with the 
belief  that  the  TXB  recipients  are  essentially  devoid  of  Ly-2  +  cytolytic  T  cell 
precursors,  this  evidence  was  interpreted  (16-18)  as  meaning  that  allosensitized, 
noncytolytic  Ly-1  + T  cells  are capable by themselves of mediating  graft  rejection, 
presumably by mediating a  delayed-type hypersensitivity reaction in the graft  (14). 
Again,  there  is  published  evidence  showing  (19-21)  that  the  rejection  of virus-  or 
carcinogen-induced  tumors in sublethally irradiated  syngeneic rats can be achieved 
by infusing helper T  cells, rather than cytolytic T  cells, generated in vitro by primed 
spleen cells in response to mitomycin C-treated tumor stimulator cells. The authors of 
these papers have considered the possibility that other cells besides helper T  cells may 
be responsible for the ultimate destruction of tumor. In support of the importance of 
helper T  cells is a more recent publication (22), which shows that the rejection of skin 
allografts in TXB rats can be achieved by the infusion of W3/25-positive helper T 
cells that  are depleted of cytolytic T  cell precursors by treatment with MRC-OX-8 
monoclonal  antibody  and  C'.  All  of these  studies  of the  passive transfer of T  cell- 
mediated immunity could be interpreted as indicating, therefore, that helper T  cells, 
rather than cytolytic T  cells, are responsible for mediating graft rejection. If so, then, 
the functional significance of the results presented in this paper is doubtful. 
It would seem premature at this stage, however, to discount the role of cytolytic T 
cells in allograft or tumor rejection on the basis of the type of evidence that has been 
published thus far. The main reason for suggesting caution is that TXB animals that 
are routinely used as recipients of sensitized helper T  cells as a  means of avoiding a 
contribution of cytolytic T  cells by the recipient, may not be suitable for this purpose. 
On the contrary, it is known that TXB animals are well endowed with cytolytic T  cell 
precursors that can give rise to functional cytolytic T  cells under appropriate stimu- 
lation.  It has been shown that spleen cells from TXB mice (23)  and even nude mice 
(24,  25)  can generate appreciable numbers of cytolytic T  cells in  vitro and in vivo, 
provided interleukin 2 is made available. It is surely significant, moreover, that Ly-1  ÷ 
helper T  cells  (26)  produce  interleukin  2  when  stimulated  with  specific antigen:  a 
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specifically sensitized  Ly-1  +  helper T  cells.  Therefore, before cytolytic T  cells  are 
discounted as being involved in graft rejection, it would seem imperative to show that 
cytolytic T  cells  are  not  being  generated  from  cytolytic  precursors  of the  TXB 
recipient at the time the graft is being rejected, because it is only at this time that one 
would expect effector T  cells to be produced (6, 27-29). It is surely relevant, in this 
connection, that in one study (22) of adoptive anti-allograft immunity with helper T 
cells,  it  was  revealed  that  an  appreciable  number  of lymphocytes displaying  the 
phenotype of cytolytic T  cells were present in the graft at the time of its rejection in 
TXB recipients. It should also be kept in mind that a striking feature common to all 
of the published studies of adoptive immunity discussed above, including our own, is 
the long delay, sometimes of >2  wk, before graft rejection commences. This surely 
means that the passively transferred helper T  cells had no immediate capacity of their 
own to initiate graft rejection, but needed an appreciable amount of time, either to 
acquire this function themselves, or to recruit recipient cells into the response. The 
long delay before graft rejection commences is certainly not in keeping with what is 
known  about  passively transferred delayed-type hypersensitivity, the  expression of 
which can be evoked routinely by injecting specific antigen  immediately after the 
passive transfer of sensitized T  cells. It would be difficult to explain, therefore, why 
Ly-1  + T  cells with  the  capacity to  initiate  delayed-type hypersensitivity reactions 
immediately after passive transfer take so long to express this  function in  a  target 
graft.  T  cell depletion studies  using anti-Ly-1  and  anti-Ly-2 monoclonal antibody 
plus C'  currently are  in  progress  in  this  laboratory. The results obtained thus  far 
(Mills, C. D., and R. J.  North, manuscript  in preparation)  indicate that the T  cells 
that can adoptively immunize against  an established P815 tumor (memory T  cells) 
are  partly  eliminated  by  treatment  with  either  antibody,  and  are  almost  totally 
eliminated by treatment with both. Experiments designed to determine whether the 
T  cells that  remain  after treatment  with  anti-Ly-2 antibody and  complement can 
cause by themselves the regression of P81 tumors in T  cell-deficient recipients if used 
in sufficient numbers, are being planned. However, the published knowledge (13) that 
the efficiency of elimination of Ly T  cell subsets by complement-mediated lysis is far 
from absolute, indicates that a knowledge of the number of Ly-2  + T  ceils that remain 
after treatment will be essential for proper interpretation of the results. 
Another feature that the examples of adoptive immunity discussed above have in 
common is that  they are all performed with mice or rats made T  cell deficient by 
thymectomy and irradiation, and restored with bone marrow cells (TXB recipients), 
or with rats immunodepressed by sublethal whole-body irradiation. The reason for 
using  TXB  recipients  for  adoptively  immunizing  against  allografts  is  obviously 
because normal recipients cannot serve as negative controls in such experiments, in 
that  they vigorously reject allografts without  the need for an  infusion of sensitized 
donor T  cells.  In the case of tumor syngrafts, however, the situation is quite different. 
An  immunogenic tumor not only grows progressively to kill its  immunocompetent 
syngeneic or semisyngeneic host, but the passive transfer of tumor-sensitized T  cells 
fails to alter this situation. On the other hand, the passive transfer of tumor-sensitized 
T  cells  causes  complete  and  permanent  regression  of tumors  growing  in  TXB 
recipients.  The reason  for the refractoriness of tumors  growing in  normal  mice to 
adoptive  immunotherapy  with  tumor-sensitized  T  cells  was  revealed  in  previous 
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acquire  a  tumor-induced  state of T  cell-mediated immunosuppression.  It was dem- 
onstrated,  for example,  that  splenic  T  cells  from  immunocompetent  mice bearing 
established  tumors  are  capable,  on  passive  transfer,  of  preventing  intravenously 
infused  tumor-sensitized  T  cells  from causing  the  regression  of established  tumors 
growing in TXB recipients. The experimental results presented in this paper serve to 
explain  how suppressor T  ceils  inhibit  the  expression of adoptive  immunity.  They 
show  that  passive  transfer  of tumor-immune  T  cells  into  normal  tumor-bearing 
recipients  results  in  a  cytolytic T  cell  response of much  lower magnitude  than  the 
cytolytic T  cell  response  generated  in  TXB  tumor-bearing recipients.  More to  the 
point,  they  show  that  an  infusion  of suppressor  spleen  cells  from  tumor-bearing 
normal  mice  causes  a  severe  depression  of the  adoptive  cytolytic  T  cell  response 
generated  in  TXB  tumor-bearing  recipients  of immune  T  cells.  This  evidence  is 
consistent  with  the interpretation  that  suppressor T  cells  function  in  this  model to 
inhibit the generation of cytolytic T  cells from cytolytic T  cell precursors. This could 
result either from a  direct  inhibitory action of suppressor cells on the replication  of 
cytolytic  precursors  or  from  an  inhibition  of the  function  of helper  T  cells.  The 
interpretation that suppressor T  cells inhibit the generation rather than the function 
of cytolytic T  cells is in keeping with the recent demonstration that  tumor-induced 
suppressor T  cells can inhibit  the production of tumor-sensitized cytolytic T  cells in 
vitro (30). 
Summary 
The results of this study with the P815 mastocytoma confirm the results of previous 
studies that showed that the passive transfer of tumor-sensitized T  cells from immu- 
nized donors can cause the regression of tumors growing in T  cell-deficient  (TXB) 
recipients,  but  not  in  normal  recipients.  The  key  additional  finding  was  that  the 
expression  of  adoptive  immunity  against  tumors  growing  in  TXB  recipients  is 
immediately preceded by a substantial production ofcytolytic T cells in the recipients' 
draining lymph node. On the other hand, failure of adoptive immunity to be expressed 
against  tumors growing in  normal  recipients was associated with  a  cytolytic T  cell 
response  of  much  lower  magnitude,  and  a  similar  tow  magnitude  response  was 
generated in TXB recipients infused with normal spleen cells and in tumor-bearing 
control mice. Because the passively transferred sensitized T cells possessed no cytolytic 
activity  of  their  own,  the  results  indicate  that  the  6-8-d  delay  before  adoptive 
immunity is expressed represents the time needed  for passively transferred helper or 
memory T  cells to give rise to a  cytolytic T  cell response of sufficient magnitude to 
destroy  the  recipient's tumor.  In support  of this  interpretation  was  the  additional 
finding that inhibition of the expression of adoptive immunity by the passive transfer 
of suppressor T  cells from tumor-bearing donors was associated with a  substantially 
reduced cytolytic T  cell response in the recipient's draining lymph node. The results 
serve to illustrate that interpretation of the results of adoptive immunization experi- 
ments requires a knowledge of the events that take place in the adoptively immunized 
recipient.  They  support  the  interpretation  that  suppressor T  cells  function  in  this 
model to "down-regulate" the production of cytolytic effector T  cells. 
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